REGENXBIO (RGNX) to Release Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX - Get Free Report) is projected to announce its earnings results after the market closes on Thursday, March 13th. Analysts expect the company to announce earnings of ($1.19) per share and revenue of $23.70 million for the quarter. Investors that wish to register for the company's conference call can do so using this link.

REGENXBIO Price Performance

RGNX traded down $0.11 during midday trading on Friday, reaching $6.34. 729,861 shares of the company's stock traded hands, compared to its average volume of 947,397. The firm has a fifty day moving average of $7.44 and a two-hundred day moving average of $9.22. The stock has a market capitalization of $314.12 million, a price-to-earnings ratio of -1.26 and a beta of 1.35. REGENXBIO has a 52 week low of $5.62 and a 52 week high of $24.26.

Analysts Set New Price Targets

A number of research analysts have commented on RGNX shares. Raymond James started coverage on REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 price target for the company. The Goldman Sachs Group downgraded REGENXBIO from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday. HC Wainwright reiterated a "buy" rating and set a $36.00 target price on shares of REGENXBIO in a report on Wednesday, January 15th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $30.00 target price on shares of REGENXBIO in a report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $33.88.

Remove Ads

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.